Mineralocorticoid receptor modulators: a patent review (2007 - 2012). (Q38161538)

30 August 2017

Mineralocorticoid receptor modulators: a patent review (2007 - 2012). (English)

1 reference

30 August 2017

Frédéric Jaisser

3

0 references

author name string

Matthieu Collin

series ordinal

1

1 reference

PubMed ID

24215301

30 August 2017

Frederic Niemann

series ordinal

2

1 reference

PubMed ID

24215301

30 August 2017

language of work or name

English

0 references

publication date

12 November 2013

1 reference

Expert Opinion on Therapeutic Patents

30 August 2017

1 reference

30 August 2017

24

1 reference

30 August 2017

2

1 reference

30 August 2017

177-183

1 reference

Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte.

30 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Extrarenal effects of aldosterone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Mineralocorticoid receptors in vascular function and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Mineralocorticoid receptor antagonists and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Primary aldosteronism: cardiovascular, renal and metabolic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Mineralocorticoid receptor gene variants as determinants of HPA axis regulation and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Salt, aldosterone, and insulin resistance: impact on the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.854772

10.1517/13543776.2014.854772

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24215301